创建MAFLD防治新模式,合力推进分层全程管理

doi:10.3969/j.issn.1672-5069.2020.05.001

Abstract

Zhang Wei, Shi Junping. A new model for prevention and treatment of MAFLD to promote whole process stratification management[J]. Journal of Practical Hepatology, 2020, 23(5): 609-611.

[1] Eslam M, Sanyal AJ, George J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 2020,158(7):1849-2014.
[2] 邵幼林,范建高.非酒精性脂肪性肝病的流行现状与危害.中华肝脏病杂志,2019,27(1):10-13.
[3] Li J, Zou B, Yeo YH, et al. Prevalence,incidence,and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol,2019,4(5):389-398.
[4] Chalmers J, Wilkes E, Harris R, et al. Development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community. Frontline Gastroenterol, 2020,11:86-92.
[5] Srivastava A, Jong S, Gola A, et al. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. BMC Gastroenterol,2019,19(1):122.
[6] 李勇,张诗雯,苏杭,等.我国分级诊疗试点现状及制约因素分析.中国药物评价,2019,36(6):406-410.
[7] 苏淑婷, 钟燕, 宓余强.非酒精性脂肪性肝病分级分期管理研究进展. 实用肝脏病杂志, 2019, 22(02):147-150.
[8] 王志翊,王仲,翁杰,等.医联体全科团队对居民家庭医生签约意愿的影响研究.中国全科医学,2018,21(27):3389-3392.
[9] Moolla A, Motohashi K, Marjot T, et al. A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. Frontline Gastroenterol,2019,10(4):337-346.
[10] Puri P, Fuchs M. Populationmanagement of nonalcoholic fatty liver disease. Fed Pract,2019,36(2):72-82.
[11] 曾雁冰,王秋鹏,方亚.厦门市糖尿病“三师共管”模式的卫生经济学评价.山东大学学报(医学版),2019,57(8):89-94+109.
[12] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.非酒精性脂肪性肝病防治指南 (2018年版).实用肝脏病杂志,2018,21(2):177-186.
[13] 李静,张梅,庄丽燕,等.社区体检人群脂肪肝流行情况及其危险因素分析.健康教育与健康促进,2019,14(06):537-540.
[14] 向润,李强.肺癌“一体化诊疗、全程管理”模式的发展现状与思考——基于四川省肿瘤医院肺癌MDT团队经验. 中国肺癌杂志,2020,23(4):211-215.

[1]	Li Junying, Zhou Ling, Chen Jinjun. Surveillance and management of individuals with high risk of NAFLD [J]. Journal of Practical Hepatology, 2020, 23(5): 612-614.
[2]	Fang Yi, Chen Yixiong, Pei Dongping, et al.. Short-term efficacy of entecavir and lactobacillus acidophilus compound combination in the treatment of patients with chronic hepatitis B and non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2020, 23(5): 634-637.
[3]	Kong Ming, Duan Zhongping, Chen Yu. Focus on nutrition in patients with chronic liver disease [J]. Journal of Practical Hepatology, 2020, 23(4): 459-461.
[4]	Hu Yiyi, Zhai Yingji, Mei Dihua, et al. Effects of extractum Phyllanthus emblica on hepatic LXRα/ FAS pathway expression in rats with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2020, 23(4): 488-491.
[5]	Hou Guanghua, Hu Qijiang, Xu Meihua , et al. Short-term efficacy of polyene phosphatidylcholine combined with metformin and fenofibrate in patients with NAFLD [J]. Journal of Practical Hepatology, 2020, 23(4): 528-531.
[6]	Zhou Na, Jiang Lei, Wu Bingbing. The potential role ofatorvastatin in treating patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2020, 23(4): 532-535.
[7]	Wu Pengbo, Song Qi, Yu Yuanjie, et al.. Effect and underlying mechanism of curcumin on oleic acid-induced steatosis of HepG2 cells in vitro [J]. Journal of Practical Hepatology, 2020, 23(3): 324-327.
[8]	Tang Xiaofei, Zhong Mengju, Shen Haijuan. Effect of naringenin Liposomes on lipid metabolism in nonalcoholic fatty liver disease rats [J]. Journal of Practical Hepatology, 2020, 23(3): 328-331.
[9]	Tang Xinya,Hou Sen,Jiao Yingying. Effect of captopril on steatosis of hepatocytes in rats with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2020, 23(3): 332-335.
[10]	Zhang Yanan, Fan Zhuping. Efficacy and safety evaluation of exercise prescription in the treatment ofpatients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2020, 23(3): 360-363.
[11]	Shen Jingyong, Guo Xiangyun, Zhou Hui, et al. Effect of radical therapy forHelicobacter pylori on serum inflammatory factors and lipid metabolism in patients with Hp positive non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2020, 23(3): 364-367.
[12]	Qian Jin, Shen Tong, Wang Yong.. Laparoscopic sleeve gastrectomy improves liver enzyme and glycolipid metabolism disorders in obese persons with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2020, 23(3): 372-375.
[13]	Wang Lijun,jin Guangfu,Wang Qi, et al.. Anterior liver fat thickness and waist circumference changes in children with metabolic syndrome [J]. Journal of Practical Hepatology, 2020, 23(3): 376-379.
[14]	Wen Bo, Wang Bingyuan. Wilson’s disease:A potentially treatable inherited disorder [J]. Journal of Practical Hepatology, 2020, 23(2): 156-158.
[15]	Zhang Meng, Chen Yi, Liu Jiao, et al. Up-regulation of lipid metabolism related genes in liver tissues of mice with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2020, 23(2): 163-166.

A new model for prevention and treatment of MAFLD to promote whole process stratification management

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments